Tharimmune (NASDAQ:THAR) Stock Price Up 3% – Should You Buy?

Tharimmune, Inc. (NASDAQ:THAR) traded up 3% during trading on Thursday . The stock traded as high as $2.11 and last traded at $2.06. 11,683 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 40,766 shares. The stock had previously closed at $2.00.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. RODMAN&RENSHAW upgraded shares of Tharimmune to a “strong-buy” rating in a research report on Friday, December 6th. Rodman & Renshaw started coverage on Tharimmune in a research note on Friday, December 6th. They issued a “buy” rating and a $17.00 price objective for the company.

Tharimmune Stock Up 3.0 %

The stock’s fifty day simple moving average is $2.09 and its 200-day simple moving average is $2.46.

Tharimmune (NASDAQ:THAR) last released its earnings results on Thursday, November 7th. The company reported ($2.45) EPS for the quarter.

Institutional Trading of Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC acquired a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned approximately 2.06% of Tharimmune at the end of the most recent reporting period. 1.16% of the stock is currently owned by institutional investors and hedge funds.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).